Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study

Introduction Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple cell types present in the lungs and can be activated by various proteases generated during acute inflammation. The cellular effe...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Critical care (London, England) Ročník 16; číslo 6; s. R238
Hlavní autori:	Schouten, Marcel, van't Veer, Cornelis, Roelofs, Joris JTH, Levi, Marcel, van der Poll, Tom
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 27.12.2012 BioMed Central Ltd
Predmet:	Animals Blood Chemokines - blood Critical Care Medicine Cytokines - blood Emergency Medicine Histochemistry Immunity - physiology Infection Inflammation Inflammation - physiopathology Intensive Leukocytes (neutrophilic) Liver Lung Medicine Medicine & Public Health Mice Mice, Inbred C57BL Mice, Knockout Neutrophil Infiltration - physiology Pathogens Pneumonia Pneumonia, Pneumococcal Pneumonia, Pneumococcal - immunology Pneumonia, Pneumococcal - mortality Pneumonia, Pneumococcal - physiopathology Proteases Proteinase Proteinase-activated receptor 1 Receptor, PAR-1 - physiology Spleen Streptococcus pneumoniae Lower Bacterial Load Barrier Protective Effect Antibacterial Defense Proinflammatory Signaling Pathway Pneumococcal Pneumonia
ISSN:	1364-8535, 1466-609X, 1364-8535, 1466-609X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Introduction Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple cell types present in the lungs and can be activated by various proteases generated during acute inflammation. The cellular effect of PAR-1 activation partially depends on the specific protease involved. We here determined the role of PAR-1 in the host response during murine pneumococcal pneumonia. Methods Wild-type (WT) and PAR-1 knockout (KO) mice were infected intranasally with viable S. pneumoniae and observed in a survival study or euthanized at 6, 24 or 48 hours of infection. Results PAR-1 KO mice had a better survival early after infection compared to WT mice. Moreover, PAR-1 KO mice had lower bacterial loads in lungs and blood at 24 hours and in spleen and liver at 48 hours after infection. This favorable response was accompanied by lower lung histopathology scores and less neutrophil influx in PAR-1 KO mice. Conclusion PAR-1 impairs host defense during murine pneumococcal pneumonia.
AbstractList	Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple cell types present in the lungs and can be activated by various proteases generated during acute inflammation. The cellular effect of PAR-1 activation partially depends on the specific protease involved. We here determined the role of PAR-1 in the host response during murine pneumococcal pneumonia.INTRODUCTIONStreptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple cell types present in the lungs and can be activated by various proteases generated during acute inflammation. The cellular effect of PAR-1 activation partially depends on the specific protease involved. We here determined the role of PAR-1 in the host response during murine pneumococcal pneumonia.Wild-type (WT) and PAR-1 knockout (KO) mice were infected intranasally with viable S. pneumoniae and observed in a survival study or euthanized at 6, 24 or 48 hours of infection.METHODSWild-type (WT) and PAR-1 knockout (KO) mice were infected intranasally with viable S. pneumoniae and observed in a survival study or euthanized at 6, 24 or 48 hours of infection.PAR-1 KO mice had a better survival early after infection compared to WT mice. Moreover, PAR-1 KO mice had lower bacterial loads in lungs and blood at 24 hours and in spleen and liver at 48 hours after infection. This favorable response was accompanied by lower lung histopathology scores and less neutrophil influx in PAR-1 KO mice.RESULTSPAR-1 KO mice had a better survival early after infection compared to WT mice. Moreover, PAR-1 KO mice had lower bacterial loads in lungs and blood at 24 hours and in spleen and liver at 48 hours after infection. This favorable response was accompanied by lower lung histopathology scores and less neutrophil influx in PAR-1 KO mice.PAR-1 impairs host defense during murine pneumococcal pneumonia.CONCLUSIONPAR-1 impairs host defense during murine pneumococcal pneumonia. Introduction Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple cell types present in the lungs and can be activated by various proteases generated during acute inflammation. The cellular effect of PAR-1 activation partially depends on the specific protease involved. We here determined the role of PAR-1 in the host response during murine pneumococcal pneumonia. Methods Wild-type (WT) and PAR-1 knockout (KO) mice were infected intranasally with viable S. pneumoniae and observed in a survival study or euthanized at 6, 24 or 48 hours of infection. Results PAR-1 KO mice had a better survival early after infection compared to WT mice. Moreover, PAR-1 KO mice had lower bacterial loads in lungs and blood at 24 hours and in spleen and liver at 48 hours after infection. This favorable response was accompanied by lower lung histopathology scores and less neutrophil influx in PAR-1 KO mice. Conclusion PAR-1 impairs host defense during murine pneumococcal pneumonia. Introduction Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple cell types present in the lungs and can be activated by various proteases generated during acute inflammation. The cellular effect of PAR-1 activation partially depends on the specific protease involved. We here determined the role of PAR-1 in the host response during murine pneumococcal pneumonia. Methods Wild-type (WT) and PAR-1 knockout (KO) mice were infected intranasally with viable S. pneumoniae and observed in a survival study or euthanized at 6, 24 or 48 hours of infection. Results PAR-1 KO mice had a better survival early after infection compared to WT mice. Moreover, PAR-1 KO mice had lower bacterial loads in lungs and blood at 24 hours and in spleen and liver at 48 hours after infection. This favorable response was accompanied by lower lung histopathology scores and less neutrophil influx in PAR-1 KO mice. Conclusion PAR-1 impairs host defense during murine pneumococcal pneumonia. Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple cell types present in the lungs and can be activated by various proteases generated during acute inflammation. The cellular effect of PAR-1 activation partially depends on the specific protease involved. We here determined the role of PAR-1 in the host response during murine pneumococcal pneumonia. Wild-type (WT) and PAR-1 knockout (KO) mice were infected intranasally with viable S. pneumoniae and observed in a survival study or euthanized at 6, 24 or 48 hours of infection. PAR-1 KO mice had a better survival early after infection compared to WT mice. Moreover, PAR-1 KO mice had lower bacterial loads in lungs and blood at 24 hours and in spleen and liver at 48 hours after infection. This favorable response was accompanied by lower lung histopathology scores and less neutrophil influx in PAR-1 KO mice. PAR-1 impairs host defense during murine pneumococcal pneumonia. Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple cell types present in the lungs and can be activated by various proteases generated during acute inflammation. The cellular effect of PAR-1 activation partially depends on the specific protease involved. We here determined the role of PAR-1 in the host response during murine pneumococcal pneumonia. Wild-type (WT) and PAR-1 knockout (KO) mice were infected intranasally with viable S. pneumoniae and observed in a survival study or euthanized at 6, 24 or 48 hours of infection. PAR-1 KO mice had a better survival early after infection compared to WT mice. Moreover, PAR-1 KO mice had lower bacterial loads in lungs and blood at 24 hours and in spleen and liver at 48 hours after infection. This favorable response was accompanied by lower lung histopathology scores and less neutrophil influx in PAR-1 KO mice. PAR-1 impairs host defense during murine pneumococcal pneumonia.
ArticleNumber	R238
Audience	Academic
Author	Schouten, Marcel van der Poll, Tom Roelofs, Joris JTH Levi, Marcel van't Veer, Cornelis
AuthorAffiliation	2 Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands 1 Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands 5 Division of Infectious Diseases; Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands 3 Department of Pathology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands 4 Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
AuthorAffiliation_xml	– name: 2 Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands – name: 5 Division of Infectious Diseases; Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands – name: 1 Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands – name: 4 Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands – name: 3 Department of Pathology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Author_xml	– sequence: 1 givenname: Marcel surname: Schouten fullname: Schouten, Marcel email: m.schouten@amc.uva.nl organization: Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam – sequence: 2 givenname: Cornelis surname: van't Veer fullname: van't Veer, Cornelis organization: Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam – sequence: 3 givenname: Joris JTH surname: Roelofs fullname: Roelofs, Joris JTH organization: Department of Pathology, Academic Medical Center, University of Amsterdam – sequence: 4 givenname: Marcel surname: Levi fullname: Levi, Marcel organization: Department of Internal Medicine, Academic Medical Center, University of Amsterdam – sequence: 5 givenname: Tom surname: van der Poll fullname: van der Poll, Tom organization: Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Division of Infectious Diseases; Academic Medical Center, University of Amsterdam
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/23270594$$D View this record in MEDLINE/PubMed
BookMark	eNqFkl1rHSEQhpeS0ny09B8UoRftzaarru5uLwoh9AsC7UV7Le7seGJwdatu4Pz7ejgnJWkKxQt1fObV15nT6sgHj1X1kjbnlPbyHQClA22eVCeUy7buBRdH99bH1WlKN01Du17yZ9Ux46xrxNCeVPF7DBl1wlpDtrc640QiAi45xJoSOy_axkSuQ8pkQoM-IbGezGu0HsnicZ0DBADtDhtv9XuiCQSfY3CuyDk9hqiL3pakvE7b59VTo13CF4f5rPr56eOPyy_11bfPXy8vrmoQss-1xr4bJ-gGOnAzmknysevH3rRGmBLhdADJkUMxRXUjGW8AW0MZ5SAYyI6fVR_2uss6zjgBlhdpp5ZoZx23KmirHp54e6024VZx2THJdgJvDwIx_FoxZTXbBOic9hjWpKgQlHPaNuL_KGe8p0x0Q0Ff79GNdqisN6FcDjtcXQje8paxjhXq_B9UGRPOtnwuGlviDxJe3Xf7x-ZdqQtQ7wGIIaWIRoHNOttdobR1ijZq10rq0EqFf_MXfyf5mDyYT4XwG4zqJqzRl9o-Qn8DiRfWEg
CitedBy_id	crossref_primary_10_1016_j_thromres_2015_03_012 crossref_primary_10_4167_jbv_2016_46_4_319 crossref_primary_10_1007_s10555_015_9599_4 crossref_primary_10_1186_cc12502 crossref_primary_10_3389_fimmu_2022_865522 crossref_primary_10_1371_journal_pone_0081298 crossref_primary_10_1007_s00253_020_10957_6 crossref_primary_10_1093_jac_dky033 crossref_primary_10_1038_srep33030 crossref_primary_10_1038_s44161_025_00681_7 crossref_primary_10_1016_j_micinf_2013_11_001 crossref_primary_10_1111_febs_16406 crossref_primary_10_1160_TH13_01_0052 crossref_primary_10_1186_s12879_014_0559_3 crossref_primary_10_4049_jimmunol_1500124 crossref_primary_10_3389_fcell_2024_1344070 crossref_primary_10_1016_j_thromres_2014_12_020 crossref_primary_10_1016_j_exppara_2014_03_023 crossref_primary_10_1128_IAI_00544_17 crossref_primary_10_1186_s12959_019_0194_8 crossref_primary_10_2119_molmed_2014_00027
Cites_doi	10.4049/jimmunol.168.7.3507 10.1074/jbc.M410381200 10.1152/physrev.00028.2003 10.1086/313954 10.1038/ni1525 10.1038/nature06663 10.1097/01.CCM.0000162381.24074.D7 10.1182/blood-2009-09-201616 10.1182/blood-2007-06-096651 10.1038/381516a0 10.1016/S0002-9440(10)62354-1 10.1186/cc8964 10.1165/rcmb.2006-0327OC 10.1182/blood-2003-09-3051 10.1002/emmm.201100145 10.1172/JCI27183 10.1002/jcp.21718 10.1186/cc9213 10.1016/j.pharmthera.2007.04.002 10.1111/j.1476-5381.2009.00449.x 10.1182/blood-2003-01-0227 10.1164/ajrccm.163.7.at1010 10.1182/blood-2010-09-310706
ContentType	Journal Article
Copyright	Schouten et al.; licensee BioMed Central Ltd. 2012 COPYRIGHT 2012 BioMed Central Ltd. Copyright ©2012 Schouten et al.; licensee BioMed Central Ltd. 2012 Schouten et al.; licensee BioMed Central Ltd.
Copyright_xml	– notice: Schouten et al.; licensee BioMed Central Ltd. 2012 – notice: COPYRIGHT 2012 BioMed Central Ltd. – notice: Copyright ©2012 Schouten et al.; licensee BioMed Central Ltd. 2012 Schouten et al.; licensee BioMed Central Ltd.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL C1K 7X8 5PM
DOI	10.1186/cc11910
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE Bacteriology Abstracts (Microbiology B)
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1364-8535 1466-609X
EndPage	R238
ExternalDocumentID	PMC3672627 A534342272 23270594 10_1186_cc11910
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- 0R~ 29F 2WC 4.4 53G 5GY 5VS 6J9 6PF AAFWJ AAJSJ AASML AAWTL ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BFQNJ BMC C6C CS3 DIK E3Z EBD EBLON EBS EJD EMOBN F5P GROUPED_DOAJ GX1 HYE IAO IHR INH INR ITC KQ8 OK1 PQQKQ RBZ ROL RPM RSV SJN SMD SOJ SV3 TR2 U2A WOQ YOC .6V AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM 7QL C1K 7X8 5PM
ID	FETCH-LOGICAL-c568t-ae87bdc79193fbfd63b78b8f4f5f93f319c63e3c0171a06230ce4f1213c52c673
IEDL.DBID	RSV
ISICitedReferencesCount	21
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000317566500024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1364-8535 1466-609X
IngestDate	Thu Aug 21 14:28:10 EDT 2025 Fri Sep 05 09:41:44 EDT 2025 Mon Oct 06 17:53:49 EDT 2025 Sat Nov 29 13:56:28 EST 2025 Sat Nov 29 10:37:51 EST 2025 Thu Apr 03 07:00:13 EDT 2025 Sat Nov 29 06:01:31 EST 2025 Tue Nov 18 22:03:24 EST 2025 Sat Sep 06 07:29:35 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	Lower Bacterial Load Barrier Protective Effect Antibacterial Defense Proinflammatory Signaling Pathway Pneumococcal Pneumonia
Language	English
License	This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c568t-ae87bdc79193fbfd63b78b8f4f5f93f319c63e3c0171a06230ce4f1213c52c673
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
OpenAccessLink	https://link.springer.com/10.1186/cc11910
PMID	23270594
PQID	1323812579
PQPubID	23462
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_3672627 proquest_miscellaneous_1551331405 proquest_miscellaneous_1323812579 gale_infotracmisc_A534342272 gale_infotracacademiconefile_A534342272 pubmed_primary_23270594 crossref_citationtrail_10_1186_cc11910 crossref_primary_10_1186_cc11910 springer_journals_10_1186_cc11910
PublicationCentury	2000
PublicationDate	20121227
PublicationDateYYYYMMDD	2012-12-27
PublicationDate_xml	– month: 12 year: 2012 text: 20121227 day: 27
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Critical care (London, England)
PublicationTitleAbbrev	Crit Care
PublicationTitleAlternate	Crit Care
PublicationYear	2012
Publisher	BioMed Central BioMed Central Ltd
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd
References	AW Rijneveld (1067_CR13) 2003; 102 S Danese (1067_CR19) 2010; 115 PA Singleton (1067_CR20) 2007; 37 CJ Scotton (1067_CR24) 2009; 119 AJ Connolly (1067_CR12) 1996; 381 JG Bartlett (1067_CR3) 2000; 31 T Peters (1067_CR6) 2009; 158 M Schouten (1067_CR14) 2010; 14 RG Jenkins (1067_CR23) 2006; 116 MS Niederman (1067_CR1) 2001; 163 M Schouten (1067_CR16) 2010; 14 JS Bae (1067_CR8) 2009; 219 PF Laterre (1067_CR2) 2005; 33 JS Bae (1067_CR7) 2007; 110 MJ Ludeman (1067_CR9) 2005; 280 AW Rijneveld (1067_CR15) 2002; 168 R Pawlinski (1067_CR17) 2004; 103 P Sen (1067_CR21) 2011; 117 E Sokolova (1067_CR5) 2007; 115 F Niessen (1067_CR11) 2008; 452 VS Ossovskaya (1067_CR4) 2004; 84 NC Kaneider (1067_CR10) 2007; 8 DC Howell (1067_CR22) 2005; 166 SL Tressel (1067_CR18) 2011; 3 20398279 - Crit Care. 2010;14(2):R65 17395891 - Am J Respir Cell Mol Biol. 2007 Aug;37(2):222-31 21591259 - EMBO Mol Med. 2011 Jul;3(7):370-84 14576054 - Blood. 2004 Feb 15;103(4):1342-7 17965715 - Nat Immunol. 2007 Dec;8(12):1303-12 17532472 - Pharmacol Ther. 2007 Jul;115(1):70-83 12702502 - Blood. 2003 Aug 1;102(3):934-9 19652365 - J Clin Invest. 2009 Sep;119(9):2550-63 19189342 - J Cell Physiol. 2009 Jun;219(3):744-51 15855637 - Am J Pathol. 2005 May;166(5):1353-65 15044683 - Physiol Rev. 2004 Apr;84(2):579-621 20682036 - Crit Care. 2010;14(4):R145 11907112 - J Immunol. 2002 Apr 1;168(7):3507-11 19845685 - Br J Pharmacol. 2009 Oct;158(4):1017-33 15665002 - J Biol Chem. 2005 Apr 1;280(13):13122-8 15891319 - Crit Care Med. 2005 May;33(5):952-61 8632823 - Nature. 1996 Jun 6;381(6582):516-9 17823308 - Blood. 2007 Dec 1;110(12):3909-16 18305483 - Nature. 2008 Apr 3;452(7187):654-8 16710477 - J Clin Invest. 2006 Jun;116(6):1606-14 10987697 - Clin Infect Dis. 2000 Aug;31(2):347-82 21252088 - Blood. 2011 Mar 17;117(11):3199-208 11401897 - Am J Respir Crit Care Med. 2001 Jun;163(7):1730-54 20018912 - Blood. 2010 Feb 11;115(6):1121-30 23448515 - Crit Care. 2013;17(1):119
References_xml	– volume: 168 start-page: 3507 year: 2002 ident: 1067_CR15 publication-title: J Immunol doi: 10.4049/jimmunol.168.7.3507 – volume: 280 start-page: 13122 year: 2005 ident: 1067_CR9 publication-title: J Biol Chem doi: 10.1074/jbc.M410381200 – volume: 84 start-page: 579 year: 2004 ident: 1067_CR4 publication-title: Physiological Reviews doi: 10.1152/physrev.00028.2003 – volume: 31 start-page: 347 year: 2000 ident: 1067_CR3 publication-title: Clin Infect Dis doi: 10.1086/313954 – volume: 8 start-page: 1303 year: 2007 ident: 1067_CR10 publication-title: Nat Immunol doi: 10.1038/ni1525 – volume: 452 start-page: 654 year: 2008 ident: 1067_CR11 publication-title: Nature doi: 10.1038/nature06663 – volume: 33 start-page: 952 year: 2005 ident: 1067_CR2 publication-title: Crit Care Med doi: 10.1097/01.CCM.0000162381.24074.D7 – volume: 115 start-page: 1121 year: 2010 ident: 1067_CR19 publication-title: Blood doi: 10.1182/blood-2009-09-201616 – volume: 119 start-page: 2550 year: 2009 ident: 1067_CR24 publication-title: J Clin Invest – volume: 110 start-page: 3909 year: 2007 ident: 1067_CR7 publication-title: Blood doi: 10.1182/blood-2007-06-096651 – volume: 381 start-page: 516 year: 1996 ident: 1067_CR12 publication-title: Nature doi: 10.1038/381516a0 – volume: 166 start-page: 1353 year: 2005 ident: 1067_CR22 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)62354-1 – volume: 14 start-page: R65 year: 2010 ident: 1067_CR16 publication-title: Crit Care doi: 10.1186/cc8964 – volume: 37 start-page: 222 year: 2007 ident: 1067_CR20 publication-title: Am J Respir Cell Mol Biol doi: 10.1165/rcmb.2006-0327OC – volume: 103 start-page: 1342 year: 2004 ident: 1067_CR17 publication-title: Blood doi: 10.1182/blood-2003-09-3051 – volume: 3 start-page: 370 year: 2011 ident: 1067_CR18 publication-title: EMBO Mol Med doi: 10.1002/emmm.201100145 – volume: 116 start-page: 1606 year: 2006 ident: 1067_CR23 publication-title: J Clin Invest doi: 10.1172/JCI27183 – volume: 219 start-page: 744 year: 2009 ident: 1067_CR8 publication-title: J Cell Physiol doi: 10.1002/jcp.21718 – volume: 14 start-page: R145 year: 2010 ident: 1067_CR14 publication-title: Crit Care doi: 10.1186/cc9213 – volume: 115 start-page: 70 year: 2007 ident: 1067_CR5 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2007.04.002 – volume: 158 start-page: 1017 year: 2009 ident: 1067_CR6 publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2009.00449.x – volume: 102 start-page: 934 year: 2003 ident: 1067_CR13 publication-title: Blood doi: 10.1182/blood-2003-01-0227 – volume: 163 start-page: 1730 year: 2001 ident: 1067_CR1 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.163.7.at1010 – volume: 117 start-page: 3199 year: 2011 ident: 1067_CR21 publication-title: Blood doi: 10.1182/blood-2010-09-310706 – reference: 12702502 - Blood. 2003 Aug 1;102(3):934-9 – reference: 23448515 - Crit Care. 2013;17(1):119 – reference: 15855637 - Am J Pathol. 2005 May;166(5):1353-65 – reference: 10987697 - Clin Infect Dis. 2000 Aug;31(2):347-82 – reference: 19189342 - J Cell Physiol. 2009 Jun;219(3):744-51 – reference: 8632823 - Nature. 1996 Jun 6;381(6582):516-9 – reference: 20018912 - Blood. 2010 Feb 11;115(6):1121-30 – reference: 11401897 - Am J Respir Crit Care Med. 2001 Jun;163(7):1730-54 – reference: 17965715 - Nat Immunol. 2007 Dec;8(12):1303-12 – reference: 19652365 - J Clin Invest. 2009 Sep;119(9):2550-63 – reference: 17532472 - Pharmacol Ther. 2007 Jul;115(1):70-83 – reference: 15891319 - Crit Care Med. 2005 May;33(5):952-61 – reference: 18305483 - Nature. 2008 Apr 3;452(7187):654-8 – reference: 21591259 - EMBO Mol Med. 2011 Jul;3(7):370-84 – reference: 17823308 - Blood. 2007 Dec 1;110(12):3909-16 – reference: 20682036 - Crit Care. 2010;14(4):R145 – reference: 19845685 - Br J Pharmacol. 2009 Oct;158(4):1017-33 – reference: 14576054 - Blood. 2004 Feb 15;103(4):1342-7 – reference: 16710477 - J Clin Invest. 2006 Jun;116(6):1606-14 – reference: 15665002 - J Biol Chem. 2005 Apr 1;280(13):13122-8 – reference: 11907112 - J Immunol. 2002 Apr 1;168(7):3507-11 – reference: 17395891 - Am J Respir Cell Mol Biol. 2007 Aug;37(2):222-31 – reference: 15044683 - Physiol Rev. 2004 Apr;84(2):579-621 – reference: 21252088 - Blood. 2011 Mar 17;117(11):3199-208 – reference: 20398279 - Crit Care. 2010;14(2):R65
SSID	ssj0017863
Score	2.1711488
Snippet	Introduction Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed... Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple... Introduction Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is expressed... Introduction: Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor-1 (PAR-1) is...
SourceID	pubmedcentral proquest gale pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	R238
SubjectTerms	Animals Blood Chemokines - blood Critical Care Medicine Cytokines - blood Emergency Medicine Histochemistry Immunity - physiology Infection Inflammation Inflammation - physiopathology Intensive Leukocytes (neutrophilic) Liver Lung Medicine Medicine & Public Health Mice Mice, Inbred C57BL Mice, Knockout Neutrophil Infiltration - physiology Pathogens Pneumonia Pneumonia, Pneumococcal Pneumonia, Pneumococcal - immunology Pneumonia, Pneumococcal - mortality Pneumonia, Pneumococcal - physiopathology Proteases Proteinase Proteinase-activated receptor 1 Receptor, PAR-1 - physiology Spleen Streptococcus pneumoniae
Title	Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study
URI	https://link.springer.com/article/10.1186/cc11910 https://www.ncbi.nlm.nih.gov/pubmed/23270594 https://www.proquest.com/docview/1323812579 https://www.proquest.com/docview/1551331405 https://pubmed.ncbi.nlm.nih.gov/PMC3672627
Volume	16
WOSCitedRecordID	wos000317566500024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1364-8535 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017863 issn: 1364-8535 databaseCode: RBZ dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1364-8535 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0017863 issn: 1364-8535 databaseCode: DOA dateStart: 19980101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1364-8535 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017863 issn: 1364-8535 databaseCode: RSV dateStart: 19970401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFD7oKuKL90t1HSKIPgW7zbW-reLigy7LqsvgS0nTBAu7naGdWfDfe5JJh-0Ioi-FNoc0JOea5HwH4BXaGOF1LijqgZryJve0boykjKmGWTQhLlZROPusjo_1fF6eJLDoYbztPh5JRk0dxVrLt9YGLDKMzm-gjdNBBk-_nm0PDJSWbJMTe5V4Ymx2Ve4Vm7N7H3LnUDTamqO7_zHKe3AnOZTkcMMB9-Ga6x7ArS_pyPwh9CcBiQFtFQ0pDJfoWjYEtZxbYrBND0jIkmz7gYRkD9I4j1GtI21HLsIuvCPLzq0vFqg0cSnTS9ead8SQdMf9HLtLjLTof5GIVvsIvh99_PbhE02FFqgVUq-ocVrVjVUlenO-9o1ktdK19twLj19QSq1kjtmArWNydJhy67gPYHBWFFYq9hj2ukXnngIxWllR1qxEet4ohfEjL-qcK1caYfhBBq_HFalsQiEPxTDOqxiNaFmlGcyAbAmXG-CNP0nehCWtgihiH9akjAIcSQC1qg4F44wXhSoy2J9QogjZSfPLkSmq0BTunXVusR4qjNXRpUG1Vv6FJtbIwUBVZPBkw0jbEaO_qgIiTgZqwmJbgoDuPW3p2p8R5ZtJVchC4X9HRquSehl2J-LZP9A8h9vo68VCNoXah71Vv3Yv4Ka9XLVDP4Praq5ncUMCn6fvf8yieP0GHVUjcg
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9UwFA8yRX1xfludGkH0KaxrPuvbGBsT7y5D59hbSNMEC1vvpb134H_vSW56Wa8g7rHNIQ3J-WzO-R2EPoKN4V7lnIAeqAirc0-q2ghCqaypBRPiYheF84mcTtXFRXmawKL7Idt9uJKMmjqKtRK71gYsMojO7zIwUyF77_uP8_WFgVSCrmpibxKPjM2myr1hczbzITcuRaOtOdq-xSofo0fJocT7Kw54gu649im6f5KuzJ-h7jQgMYCtIqGE4RpcyxqDlnNzCLbJHg5Vkk3X41DsgWvnIap1uGnxVfgL7_C8dcurGShNOMr00DbmCzY45bhfwnSJkWbdbxzRap-jn0eHZwfHJDVaIJYLtSDGKVnVVpbgzfnK14JWUlXKM889vAEptYI6agO2jsnBYcqtYz6AwVleWCHpC7TVzlr3CmGjpOVlRUugZ7WUED-yosqZdKXhhu1l6NNwItomFPLQDONSx2hECZ12MEN4TThfAW_8TfI5HKkOoghzWJMqCmAlAdRK73PKKCsKWWRoZ0QJImRHwx8GptBhKOSdtW627DXE6uDSgFor_0ETe-RAoMoz9HLFSOsVg78qAyJOhuSIxdYEAd17PNI2vyLKNxWyEIWE7w6MppN66Tc34vV_0LxHD47PTiZ68nX67Q16CH5fbGpTyB20teiW7i26Z68XTd-9i4L1B0iDI2o
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB9KleKL3x_RVlcQfQpNs5_xrbQ9FOtxoJa-hWSzi4E2d-TuCv73ziSbozlBxMdkh82yO5-Znd8AvEMbI71JZIx6oIxFlfi4rAoVc64rbtGEuK6LwsW5nk7N5WU22wE51MJ0t92HlGRf00AoTc3qcFH5XsSNOrSWcMkwUr8jqFMQBenfLjbJA20U7-tjbxOPDM-2-r1lf7bvRm4lSDu7M3nwnyt-CPeDo8mOe854BDuueQx7X0Mq_Qm0M0JoQBsWU2nDDbqcFUPt5xYYhMdHjKon63bJqAiEVc5jtOtY3bBr-jvv2KJx6-s5KlM84vDQ1MVHVrBw9_0KpwsMNm9_sQ7F9in8mJx9P_kUhwYMsZXKrOLCGV1WVmfo5fnSV4qX2pTGCy89vkHptYo7bglzp0jQkUqsE55A4qxMrdL8Gew288a9AFYYbWVW8gzpRaU1xpUiLROhXVbIQhxF8H44ndwGdHJqknGVd1GKUXnYwQjYhnDRA3L8SfKBjjcnEcU5bBEqDXAlBHaVH0suuEhTnUawP6JE0bKj4bcDg-Q0RPfRGjdfL3OM4dHVQXWX_YWm652DAayM4HnPVJsVox-rCSknAj1itw0BoX6PR5r6Z4f-zZVOVarxuwPT5UHtLLc34uU_0LyBvdnpJD__PP3yCu6hO9j1ukn1Puyu2rU7gLv2ZlUv29edjP0GrSIsTg
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protease-activated+receptor-1+impairs+host+defense+in+murine+pneumococcal+pneumonia%3A+a+controlled+laboratory+study&rft.jtitle=Critical+care+%28London%2C+England%29&rft.au=Schouten%2C+Marcel&rft.au=van%27t+Veer%2C+Cornelis&rft.au=Roelofs%2C+Joris+JTH&rft.au=Levi%2C+Marcel&rft.date=2012-12-27&rft.issn=1364-8535&rft.volume=16&rft.issue=6&rft.spage=R238&rft.epage=R238&rft_id=info:doi/10.1186%2Fcc11910&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1364-8535&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1364-8535&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1364-8535&client=summon